<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251964</url>
  </required_header>
  <id_info>
    <org_study_id>NL49534.100.14</org_study_id>
    <secondary_id>2013-005269-37</secondary_id>
    <nct_id>NCT02251964</nct_id>
  </id_info>
  <brief_title>Rituximab in Interstitial Pneumonitis</brief_title>
  <acronym>RITUX-IP</acronym>
  <official_title>Rituximab in Life Threatening Therapy Resistant Progressive Interstitial Pneumonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Adams</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will address rare immune mediated inflammatory diseases (IMIDs) involving the&#xD;
      lungs, i.e. interstitial pneumonitis (IP). The main objective of this study is to assess the&#xD;
      effects of rituximab (RTX) as a rescue therapy for progressive IMID-IP patients. The primary&#xD;
      study parameter is pulmonary function.&#xD;
&#xD;
      The secondary objectives are to explore the application of imaging with radiolabeled RTX as&#xD;
      early predictor for efficacy of RTX, to study the effects of RTX treatment on quality of&#xD;
      life, and to further elucidate the pathophysiology of IMID-IP by analyzing biochemical&#xD;
      markers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function (VC, DLCO)</measure>
    <time_frame>6 - 12 months</time_frame>
    <description>establish a change from the downward decline in pulmonary function (absolute values and values predicted of VC = Vital Capacity and DLCO = Diffusion capacity of Lung Carbon monoxide)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Zr-89 Immuno PET</measure>
    <time_frame>3, 6 days after injection</time_frame>
    <description>This is a scan with radiolabelled rituximab (visualizing rituximab activity in the lungs). Calculated activity (SUV) in the lungs vs. blood pool vs liver vs.control group (n=15) is measured with standard deviation. The amount of uptake in the lungs and the clinical response of patients will be correlated to determine a correlation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Diseases, Interstitial</condition>
  <condition>Pneumonitis, Interstitial</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single arm study with Zr-89-rituximab immuno PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>2 times 1000mg dose at 14 days interval treatment</description>
    <arm_group_label>rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Zr-89-rituximab immuno PET/CT</intervention_name>
    <description>Immuno labeled PET/CT of the lungs</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>Immuno PET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in the study, subjects must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Age 18 to 70 years&#xD;
&#xD;
          -  No previous therapy with rituximab&#xD;
&#xD;
          -  At least 2 pulmonary function tests within past 6 months&#xD;
&#xD;
          -  Diagnosis of co-existing IMID and a severe and / or progressive IP characterized by 3&#xD;
             out of the following items:&#xD;
&#xD;
          -  Respiratory symptoms consistent with interstitial lung disease&#xD;
&#xD;
          -  Diagnosis of usual interstitial pneumonia (UIP), non-specific interstitial pneumonia&#xD;
             (NSIP), organizing pneumonia (OP) or a mixed form of UIP / NSIP / OP by either of the&#xD;
             following:&#xD;
&#xD;
          -  Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or&#xD;
             probable UIP / NSIP / OP&#xD;
&#xD;
          -  High Resolution Computer Tomography (HRCT) scan showing definite or probable&#xD;
             UIP/NSIP/OP/mixed&#xD;
&#xD;
          -  Forced Vital Capacity (FVC) &lt; 50% predicted and/or diffusing capacity of the lung for&#xD;
             carbon monoxide (DLCO) &lt; 40% predicted or worsening of lung function as demonstrated&#xD;
             by any one of the following within the past year:&#xD;
&#xD;
          -  &gt; 10% decrease in FVC&#xD;
&#xD;
          -  &gt; 15% decrease in DLCO&#xD;
&#xD;
          -  Therapy resistance to 1st (corticosteroids) and 2nd line therapy(cyclophosphamide or&#xD;
             azathioprine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          -  Residual volume &gt;120% predicted at screening&#xD;
&#xD;
          -  DLCO &lt;25% of predicted value at screening + resting Oxygen Saturation (SAO2) without&#xD;
             external oxygen &lt;90%&#xD;
&#xD;
          -  History of unstable or deteriorating cardiac or neurological disease&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Hematology lower than specified limits (leucocytes)&#xD;
&#xD;
          -  Positive HIV, hepatitis B or C serology&#xD;
&#xD;
          -  Pre-existing conditions which lead to a life expectancy of less than 6 months&#xD;
&#xD;
          -  Receipt of any vaccine, particularly live viral vaccines, within 4 weeks before first&#xD;
             rituximab dose&#xD;
&#xD;
          -  Hypersensitivity for murine proteins&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Fever (&gt;37,9 Â°C) at presentation is reason to delay therapy by 1 week&#xD;
&#xD;
          -  Evidence of active infection is reason to postpone rituximab treatment until no&#xD;
             further signs of active infection&#xD;
&#xD;
          -  Severe renal impairment is not a contraindication for rituximab therapy, however, if&#xD;
             patients (might) require dialysis frequently they will be excluded from the study&#xD;
             group&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J C Grutters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Human Adams</investigator_full_name>
    <investigator_title>Prof. Dr. D.H. Biesma</investigator_title>
  </responsible_party>
  <keyword>IMID</keyword>
  <keyword>Interstitial Pneumonitis</keyword>
  <keyword>rituximab</keyword>
  <keyword>Immuno PET</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

